rSj26-Sj32-Immunogold-IgG-Dot-ELISA用于急性日本血吸虫病的诊断价值

目的 探讨rsj26-Sj32-Immunogold-IgG-Dot-ELISA用于急性日本血吸虫病患者的诊断价值.方法 利用纯化的rsj26-Sj32融合蛋白和日本血吸虫成虫抗原(SjAWA)建立Immunogold-IgG-Dot-ELISA方法检测急性日本血吸虫病患者血清,并以华支睾吸虫病、卫氏并殖吸虫病、棘球蚴病、乙型肝炎、肺结核病患者和健康人血清作对照.比较检测结果.结果 rsj26-Sj32和SjAWA检测急性日本血吸虫病患者的阳性检出率均为100%,特异性分别为97.67%和95.35%;SjAWA与华支睾吸虫病和卫氏并殖吸虫病血清均存在不同程度的交叉反应.结论 纯化的rSi26-Si32融合蛋白是一种较好的免疫诊断抗原.     

rSj26-Sj32-IgG4-ELISA法用于慢性日本血吸虫病疗效考核价值的研究

目的 探讨rSj26-Sj32-IgG4-ELISA法用于慢性日本血吸虫病疗效考核价值的研究。方法 采用rSj26-Sj32融合蛋白和日本血吸虫成虫粗抗原(SjAWA)作为包被抗原建立ELISA方法检测慢性日本血吸虫病患者体内治疗前后血清中特异性IgG4抗体水平的变化。结果 rSj26-Sj32融合蛋白组中,化疗前、化疗后3个月、化疗后6个月和化疗后12个月血清中IgG4抗体阳性率分别为95.00%、77.27%、60.00%和30.43%;而SjAWA组中血清特异性IgG4抗体阳性率分别为97.50%、81.82%、55.00%和34.78%。结论 rSj26-Sj32-IgG4-ELISA法可用于慢性日本血吸虫病的疗效考核。     

日本血吸虫谷胱甘肽-S-转移酶在虫卵阶段的定位

目的探讨谷胱甘肽-S-转移酶(Sj26GST)在虫卵阶段的表达、定位和重组蛋白(rSj26GST)的免疫诊断价值。方法从感染日本血吸虫尾蚴6周的兔肝脏中分离虫卵,分别用RT-PCR和免疫印迹(Western blotting)法检测Sj26GST基因在虫卵阶段的转录和翻译;同时用兔肝做免疫组化观察Sj26GST在虫卵内的分布。利用纯化的rSj26GST和日本血吸虫可溶性虫卵抗原(SEA),采用间接ELISA法检测急、慢性血吸虫病患者和正常人血清。结果RT-PCR从血吸虫虫卵中扩增670bp的基因片断,Western blotting证明在虫卵阶段Sj26GST的表达;同时免疫组化显示Sj26GST主要分布在虫卵内毛蚴两边的侧腺。rSj26GST检测急、慢性血吸虫病患者和正常人血清的阳性率分别为92%、80%和0;用SEA检测以上标本,阳性率分别为96%、84%和2%。结论Sj26GST是SEA的主要组分之一,能刺激机体产生高滴度的抗体;rSj26GST为抗原诊断日本血吸虫病显示出高度的敏感性和特异性,具有实用价值。     

棘球蚴病患者血清特异性IgE免疫应答的研究

以纯化的棘球蚴抗原对棘球蚴病患者、非棘球蚴病患者和健康人血清进行斑点免疫结合试验,以检测棘球蚴病患者特异性IgE抗体。当血清稀释度为1:100时,79例棘球蚴病患者血清的阳性符合率为94.9％,69例非棘球蚴病患者血清和119名健康人血清的假阳性率为3.2％,标准误差为2.79％。不同部位的棘球蚴病患者血清的阳性符合率分别为:肝肺并发棘球蚴病100.0％,肝棘球蚴病97.5％,肺棘球蚴病93.5％,腹腔棘球蚴病75.0％。阻断试验、替代试验和诊断试验结果提示棘球蚴病患者特异性IgE免疫应答检测试验可以作为棘球蚴病血清学诊断的参考试验之一。     

棘球蚴感染的检测分析

目的探讨动物宿主棘球蚴感染的检测方法,为绦虫感染的治疗与预防提供参考。方法选择泡状棘球蚴病羊血清和囊型棘球蚴病羊血清各100份,建立AgB原核表达体系,采用十二烷基硫酸钠聚丙烯酰胺凝胶电泳(SDS-PAGE)分析及酶联免疫吸附测定(ELISA)进行血清学诊断评价。结果联合表达抗原AgBs对囊型棘球蚴病羊血清的敏感性和特异性均为90.0%,明显高于AgB1对囊型棘球蚴病羊血清的敏感性和特异性(分别为70.0%、56.0%)(P<0.05)。结论联合表达抗原AgBs对囊型棘球蚴病的诊断价值优于AgB1。     

rSj26GST-Sj32融合蛋白-IgG-ELISA用于慢性日本血吸虫病诊断的研究

目的 探讨rSj26GST-Sj32-IgG-ELISA用于慢性日本血吸虫病的诊断价值.方法 将含有重组质粒pET32α-Sj26GST-Sj32的大肠埃希菌BL21(DE3)用异丙基硫代-β-D-半乳糖苷(IPTG)诱导表达,表达产物进行SDS-PAGE电泳,用Ni-NTA试剂盒纯化重组Sj26GST-Sj32(rS...     

协同凝集试验在胆囊棘球蚴病的诊断应用

目的 建立一种简便快速、经济实用的胆囊棘球蚴病（cystic echinococcosis,CE）的实验诊断方法。方法 以自制兔抗棘球蚴抗血清建立一种检测CE患者血清或尿液中棘球蚴抗原（H-Ag）的玻片协同凝集（Co-A）试验,并用于检测30例CE患者、20例其他寄生虫病和25例健康人血清及尿液中的H-Ag,并评价该法的灵敏度、特异度、阳性预测值和阴性预测值。结果 CE患者浓缩尿液和血清中H-Ag的总检出率分别为77%及83%,其中手术诊断CE组浓缩尿液和血清中H-Ag的检出率分别为83%及92%,超声检查证实CE组为75%及88%,临床诊断CE为70%及80%,应用Co-A试验检测患者浓缩尿液和血清中H-Ag的灵敏度、特异度、阳性预测值和阳性预测值分别为77%,87%,93%和96%;89%,93%,86%和92%。结论 Co-A试验是临床上诊断CE的一种简便快速、经济实用的实验诊断方法,易于推广使用。     

重组Sj31-b的表达及其免疫诊断价值的研究

目的 探讨日本血吸虫重组31KD蛋白片（rSJ31-b)的免疫诊断价值。方法 表达并纯化rSj31-b，用免疫印迹方法（EITB）检测纯化的rSj-b的免疫活性，以rSj31-b-ELISA分别检测慢性日本血吸虫病人及正常人的血清。结果 纯化的重组Sj31-b具有较好的免疫活性；用其rSj31-b－ELISA检测52份慢性日本血吸虫病人血清及83份正常人血清，敏感性和特异性与常规应用的天然抗原SEA（可溶性虫卵抗原）差异无显性。检测治疗12个月后的慢性日本血吸虫病人血清，阴转率85.0%，明显优于SEA－ELISA。结论 rSj31-b具有较好的敏感性和特异性，且有一定的疗效考核价值，可替代SEA用于慢性日本血吸虫病人的诊断。     

抗rSj14-3-3单克隆抗体检测循环抗原及疗效考核价值的初步研究

目的探讨抗重组日本血吸虫14-3-3(rSj14-3-3)的单克隆抗体检测血吸虫循环抗原对血吸虫病疗效考核的价值.方法制备纯化的抗日本血吸虫14-3-3的单克隆抗体,以纯化的兔抗rSj14-3-3多抗和酶标羊抗兔多抗为检测系统的酶联免疫吸附试验(P-M-ELISA)法,分别对同批治疗前及治疗后2、4、6、12个月的血吸虫病患者和感染兔血清进行检测,并与常规检测抗体的可溶性虫卵抗原-酶联免疫吸附试验(SEA-ELISA)法比较.结果 P-M-ELISA法对治疗前血吸虫病患者检测阳性率为98.2%,而检测抗体的SEA-ELISA为95.5%.P-M-ELISA法对治愈后2、4、6、12个月血清循环抗原检测阴转率分别为17.7%、41.9%、55%、85%,而检测抗体的SEA-ELISA法分别为3.2%、6.5%、12.5%、15%.结论该法既有较好的诊断价值,又有较好的疗效考核价值.     

深圳市疑似寄生虫病例血清抗体检测结果分析

目的利用疾控检测平台检测寄生虫感染疑似病例血清抗体,为医院诊疗寄生虫病提供技术依据。方法采用寄生虫病诊断标准的ELISA方法,对深圳市、区属医院送检的华支睾吸虫、日本血吸虫、广州管圆线虫及棘球蚴病疑似病例血样进行血清抗体Ig G检测。结果深圳市、区属医院896份寄生虫病疑似病例血清样本4种寄生虫抗体总阳性率为14.1%(126/896),其中深圳市、区属医院血样抗体阳性率分别为13.6%(100/734)、16.0%(26/162),抗体阳性率间的差异无统计学意义(χ2=0.646,P0.05);华支睾吸虫、日本血吸虫、广州管圆线虫及棘球蚴的血清抗体阳性率分别为16.2%(38/234)、17.8%(48/269)、11.6%(22/189)、8.8%(18/204)。结论深圳市存在华支睾吸虫、日本血吸虫、广州管圆线虫及棘球蚴病病例,应加强寄生虫病防治的宣传、监测和管理。     

Construction and Expression of DNA Vaccine pIRES-Sj97-Sj14-Sj26 and Its Immunogenicity in Mice

To find a new preventive strategy for the infection of Schistosoma japonica, plasmid pIRES-Sj97-Sj 14-Sj26 that contains fatty binding protein （Sj 14）, GST （Sj26） and paramyocin （Sj97） that are expressed on the membrane, was constructed. RT-PCR was used to detect the expression of Sj 14 mRNA, Sj26 mRNA and Sj97 mRNA in the Hela cells, the indirect immunofluorescent test was employed for the detection of the expression of trans-membrane Sj26 after the plasmid was transfected into Hela cells. Fifty BALB/c mice were randomly divided into 5 groups and plRES-Sj97-SjI4-Sj26 plasmid DNA, plRES-Sj 14-Sj26 plasmid DNA, plRES-Sj26 plasmid DNA, plRES blank vector and normal saline were respectively injected into the quadriceps muscles of thigh Eight weeks after the immunization the mice were killed and significantly higher level of IgG was detected in the plRES-Sj97-Sj 14-Sj26 group as compared with the plRES blank vector, normal saline and plRES-Sj26 groups （P〈 0.01） and the plRES-Sj 14-Sj26（P〈0.05）. Single splenocyte suspension was prepared to detected the level of IFN-T by ELISA and the lymphocyte stimulating index （SI） by MTT. SI was significantly higher of in the plRES-Sj97-Sj 14-Sj26 group than in other groups （P〈 0.01）, while the IFN-T level was significantly higher the plRES-Sj97-Sj 14-Sj26 group than in plRES blank vector and normal saline groups （P〈0.01）, but no significant differences were found when compared with plRES-Sj 14-Sj26 and plRES-Sj26 groups. Flow cytometery showed that the percentages of CD4＋ and CD8＋ T cells were much higher in the plRES-Sj97-Sj 14-Sj26 group （P〈 0.01, P〈0.05）. It was concluded that plRES-Sj97-Sj 14-Sj26 vaccine may induce stronger immune response in BALB/c mice.     

Construction and Expression of Bivalent Membrane-anchored DNA Vaccine Encoding Sj14FABP and Sj26GST Genes

In order to construct a eukaryotic co-expression plasmid containing membrane-anchored Sjc14FABP and Sjc26GST genes and identify their expression in vitro, Sj 14 and Sj26 genes were obtained by RT-PCR with total RNA of Schistosoma japonicum adult worms as the template and cloned into eukaryotic expression plasmid pVAC to construct recombinant plasmids pVAC-Sj14 and pVAC-Sj26. Then a 23 amino-acid signal peptide of human interleukin-2 (IL-2) upstream Sj14 or Sj26 gene and a membrane-anchored sequence containing 32 amino-acids of carboxyl-terminal of human plaeental alkaline phosphatase (PLAP) downstream were amplified by PCR as the template of plasmid pVAC-Sj14 or pVAC-Sj26 only to get two gene fragments including Sj14 gene and Sj26 gene. The two modified genes were altogether cloned into a eukaryotic co-expression plasmid pIRES, resulting in another new recombinant plasmid pIRES-Sj26-Sj 14. The expression of Sl14 and Sl26 genes was detected by RT-PCR and indirect immunofluorescent assays (IFA) when the plasmid pIRES-Sj26-Sj14 was transfected into eukaryotic Hela cells. Restriction enzyme analysis, PCR and sequencing results revealed that the recombinant plasmids pVAC-Sj14, pVAC-Sj26 and pIRES-Sj26-Sj 14 were successfully constructed and the expression of modified Sj 14 and Sj26 genes could be detected by RT-PCR and IFA. A bivalent membrane-anchored DNA vaccine encoding Sj14 and Sj26 genes was acquired and expressed proteins were proved to be mostly anchored in cellular membranes.     

Construction and Expression of Bivalent Membrane-anchored DNA Vaccine Encoding Sj14FABP and Sj26GST Gene

In order to construct a eukaryotic co-expression plasmid containing membrane-anchored Sjc14FABP and Sjc26GST genes and identify their expression in vitro, Sj 14 and Sj26 genes were ob- tained by RT-PCR with total RNA of Schistosoma japonicum adult worms as the template and cloned into eukaryotic expression plasmid pVAC to construct recombinant plasmids pVAC-Sjl4 and pVAC-Sj26. Then a 23 amino-acid signal peptide of human interleukin-2 （IL-2） upstream Sj 14 or Sj26 gene and a membrane-anchored sequence containing 32 amino-acids of carboxyi-terminal of human placental alkaline phosphatase （PLAP） downstream were amplified by PCR as the template of plasmid pVAC-Sj14 or pVAC-Sj26 only to get two gene fragments including Sj14 gene and Sj26 gene. The two modified genes were altogether cloned into a eukaryotic co-expression plasmid plRES, resulting in another new recombinant plasmid plRES-Sj26-Sj14. The expression of Sj 14 and Sj26 genes was detected by RT-PCR and indirect immunofluorescent assays （IFA） when the plasmid plRES-Sj26-Sj 14 was transfected into eukaryotic Hela cells. Restriction enzyme analysis, PCR and sequencing results revealed that the recombinant plasmids pVAC-Sj14, pVAC-Sj26 and plRES-Sj26-Sj 14 were successfully constructed and the expression of modified Sj 14 and Sj26 genes could be detected by RT-PCR and IFA. A bivalent membrane-anchored DNA vaccine encoding Sj 14 and Sj26 genes was acquired and expressed proteins were proved to be mostly anchored in cellular membranes.     

日本血吸虫成虫脲溶42 kD蛋白的分离及其初步诊断应用

目的 :分离日本血吸虫成虫脲溶抗原中有免疫学活性的抗原分子 ,探讨其诊断血吸虫病的效果。方法 :利用SDS PAGE及免疫印迹法分析日本血吸虫成虫脲溶抗原 ,采用电泳层析法分离有免疫活性的 4 2kD蛋白 ,ELISA分析 4 2kD蛋白诊断血吸虫病的灵敏度和特异性。结果 :电泳层析获得了具有免疫学活性的 4 2kD蛋白 ;分离的 4 2kD蛋白诊断血吸虫病的灵敏度和特异性分别为 88.0 9%和 97.0 6 %。结论 :日本血吸虫成虫脲溶 4 2kD蛋白是一种日本血吸虫的血清学抗原 ,可用于血吸虫病诊断     

重组核酸疫苗诱导小鼠抗血吸虫感染的免疫学研究

目的为日本血吸虫病的防治寻求新的高效联合基因免疫策略。方法构建共表达日本血吸虫相对分子质量23000表膜蛋白(Sj23)基因与鼠IL12基因的核酸疫苗质粒pVIVO2IL12Sj23,转染HEK293细胞,通过RTPCR,Westernblot及ELISA法检测Sj23和IL12蛋白的表达。接种并攻击感染BALB/c小鼠,以减虫率和减卵率评价其免疫保护力,同时设攻击感染对照组、空白质粒pVIVO2组、pVIVO2IL12组和pVIVO2Sj23组。用ELISA法和WesternBlot分析免疫小鼠血清中抗体。以脾细胞培养法检测经SEA刺激后,小鼠脾细胞分泌IFNγ和IL4的水平。并以FCM分析脾细胞亚群。结果经瞬时转染HEK293细胞证明质粒pVIVO2IL12Sj23能在体外进行表达。免疫小鼠后获得了4553%的减虫率和5835%的减卵率,较单价DNA疫苗pVIVO2Sj23免疫效果好(P<005)。ELISA法和WesternBlot检测抗体结果表明免疫小鼠产生了抗Sj23特异性IgG抗体。pVIVO2IL12Sj23免疫组IFNγ的水平较对照组显著升高而IL4水平较对照组低。攻击感染后各实验组小鼠脾细胞的CD4+,CD8+亚群比率无显著差别(P>005)。结论pVIVO2IL12Sj23DNA疫苗具有诱导BALB/c小鼠产生较好的抗血吸虫感染免疫保护效果。细胞因子IL12作为基因佐剂,具有诱导Th1型免疫反应从而增强DNA疫苗免疫保护性的作用。     

Construction and expression of DNA vaccine pIRES-Sj97-Sj14-Sj26 and its immunogenicity in mice

Summary To find a new preventive strategy for the infection of Schistosoma japonica, plasmid pIRES-Sj97-Sj14-Sj26 that contains fatty binding protein (Sj14), GST (Sj26) and paramyocin (Sj97) that are expressed on the membrane, was constructed. RT-PCR was used to detect the expression of Sj14 mRNA, Sj26 mRNA and Sj97 mRNA in the Hela cells, the indirect immunofluorescent test was employed for the detection of the expression of trans-membrane Sj26 after the plasmid was transfected into Hela cells. Fifty BALB/c mice were randomly divided into 5 groups and pIRES-Sj97-Sj14-Sj26 plasmid DNA, pIRES-Sj14-Sj26 plasmid DNA, pIRES-Sj26 plasmid DNA, pIRES blank vector and normal saline were respectively injected into the quadriceps muscles of thigh. Eight weeks after the immunization the mice were killed and significantly higher level of IgG was detected in the pIRES-Sj97-Sj14-Sj26 group as compared with the pIRES blank vector, normal saline and pIRES-Sj26 groups (P<0.01) and the pIRES-Sj14-Sj26(P<0.05). Single splenocyte suspension was prepared to detected the level of IFN-γ by ELISA and the lymphocyte stimulating index (SI) by MTT. SI was significantly higher of in the pIRES-Sj97-Sj14-Sj26 group than in other groups (P<0.01), while the IFN-γ level was significantly higher the pIRES-Sj97-Sj14-Sj26 group than in pIRES blank vector and normal saline groups (P<0.01), but no significant differences were found when compared with pIRES-Sj14-Sj26 and pIRES-Sj26 groups. Flow cytometery showed that the percent-ages of CD4+ and CD8+ T cells were much higher in the pIRES-Sj97-Sj14-Sj26 group (P< 0.01, P<0.05). It was concluded that pIRES-Sj97-Sj14-Sj26 vaccine may induce stronger immune response in BALB/c mice. This project was supported by grants from National Natural Sciences Foundation of China (No. 30471603).     

卫氏肺吸虫重组抗原的制备及初步应用研究

目的：纯化重组细菌Pw-1／pRSET B／BL21的表达产物肺吸虫重组抗原，复性后以ELISA法检测肺吸虫病患者、其他寄生虫病患者和正常人血清，评价其敏感性、特异性和应用前景。方法：通过分步洗涤及透析对细菌重组蛋白进行初步纯化．进一步做快速液相层析纯化，比较前后两法的纯化效果。初步纯化产物经氧化／还原型谷胱苷肽复性后即为重组蛋白抗原(以下简称重组抗原)。用该重组抗原，以ELISA法检测肺吸虫、血吸虫、肝吸虫、囊虫和包虫病患者以及正常人血清中相应抗体，并与卫氏肺吸虫粗抗原做比较。结果：经分步洗涤及透析纯化后的重组抗原纯度已较高，快速液相层析进一步纯化效果不明显。以初步纯化后经复性的重组抗原进行ELISA法检测肺吸虫病患者血清，敏感性为91．07％，与其他寄生虫病患者和正常人血清均无交叉反应；粗抗原检测肺吸虫病患者血清敏感性虽为100％，但与其他寄生虫病患者和正常人血清交叉反应率分别为：血吸虫病11．43％，肝吸虫病4．84％，囊虫病3．22％，包虫病5．88％，正常人为2．5％。结论：研究制备的重组抗原应用于肺吸虫病的免疫诊断特异性较高。     

日本血吸虫不同发育阶段抗原检测IgG及IgG_4的疗效考核价值

目的 :建立具有疗效考核价值的抗原 -抗体检测系统。方法 :用日本血吸虫不同发育阶段抗原 (AWA、AMA、AESA、SEA、SIEA)检测治疗前及治疗后不同时间慢性血吸虫病人血清中特异性IgG及IgG4 并测定肺吸虫病人、肝吸虫病人和健康人血清的交叉反应性。结果 :不同发育阶段抗原 -IgG检测系统间对慢性血吸虫病人、肺吸虫病人、肝吸虫病人和健康人血清测试的阳性率无显著性差异 (P >0 .0 5 ) ,慢性血吸虫病人治疗后 12个月IgG的阴转率以SIEA最高 (90 .0 % ) ,其次为AMA(77.5 % ) ,最低为AESA(2 0 .0 % ) ;检测慢性血吸虫病人治疗前的特异性IgG4 的阳性率AWA最高 (85 .0 % ) ,其次为AMA(80 .0 % ) ,最低的为SIEA(37.5 % ) ,治疗后 12个月的IgG4 阴转率SIEA最高 (97.5 % ) ,其次为AMA(95 .0 % )和AWA(85 .0 % ) ,最低的为SEA(6 2 .5 % )。结论 :AMA -IgG、SIEA -IgG、AWA -IgG4 和AMA -IgG4 检测系统具有较好的疗效考核价值 ,且以SIEA -IgG和AMA -IgG4 两个检测系统最好。